February 2015

CRANBURY, N.J., Feb. 20, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website (https://www.reconnectstudy.com) in support of its phase 3 reconnect study with bremelanotide for …

Palatin Launches reconnectstudy.com in Support of Bremelanotide Phase 3 Program for Female Sexual Dysfunction Read More »

CRANBURY, N.J., Feb. 13, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2014.  “We achieved a significant clinical and corporate milestone by advancing bremelanotide …

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on February 13, 2015 Read More »

CRANBURY, N.J., Feb. 9, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2015 operating results on Friday, February 13, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, …

Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2015 Results Teleconference and Webcast to be held on February 13, 2015 Read More »

CRANBURY, N.J., Feb. 6, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 17th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City. …

Palatin Technologies To Present At The BIO CEO & Investor Conference Read More »